|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Genzyme_Genetics
|
|
gptkbp:activities
|
tyrosine kinase inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Gleevec
|
|
gptkbp:clinical_trial
|
Phase III trials
Phase I trials
Phase II trials
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
severe liver impairment
hypersensitivity to imatinib
|
|
gptkbp:developed_by
|
gptkb:Novartis
|
|
gptkbp:discovered_by
|
gptkb:Dr._Nicholas_Lydon
|
|
gptkbp:dissolved
|
soluble in water
soluble in ethanol
|
|
gptkbp:duration
|
long-term therapy
|
|
gptkbp:education
|
recognizing side effects
importance of adherence
dietary considerations
drug interactions awareness
|
|
gptkbp:events
|
regular monitoring required
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Imatinib
|
|
gptkbp:ingredients
|
C29 H31 N7 O2 S
|
|
gptkbp:interacts_with
|
CY P2 C19
CY P3 A4
CY P1 A2
|
|
gptkbp:is_atype_of
|
L01 X E03
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
kidney function tests
|
|
gptkbp:is_used_for
|
gptkb:chronic_myeloid_leukemia
gptkb:gastrointestinal_stromal_tumors
|
|
gptkbp:lifespan
|
15-20 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
edema
|
|
gptkbp:targets
|
gptkb:BCR-ABL_fusion_protein
|
|
gptkbp:treatment
|
with other cancer drugs
|
|
gptkbp:type_of
|
152459-95-5
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:water_resistance
|
BCR-ABL mutations
alternative signaling pathways
drug efflux pumps
|
|
gptkbp:weight
|
493.6 g/mol
|
|
gptkbp:year_created
|
gptkb:1993
|